公开(公告)号：US10689451B2

公开(公告)日：2020-06-23

申请号：US15980411

申请日：2018-05-15

申请人： Novartis AG

发明人： Marta Cosenza ,  Christoph Stark

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K9/00 ,  A61K47/18 ,  A61K47/26 ,  C07K14/715 ,  A61K39/00

摘要： Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.

公开(公告)号：US12054555B2

公开(公告)日：2024-08-06

申请号：US17127755

申请日：2020-12-18

申请人： NOVARTIS AG

发明人： Marta Cosenza ,  Christoph Heusser ,  Julia Neugebauer ,  Eveline Schaadt ,  Stefanie Urlinger ,  Maximilian Woisetschlaeger

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K9/20 ,  A61K39/395 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  C07K14/705 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K9/2018 ,  A61K39/39591 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  C07K14/70578 ,  C07K16/2896 ,  A61K39/39533 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73

摘要： Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

公开(公告)号：US10899841B2

公开(公告)日：2021-01-26

申请号：US16294374

申请日：2019-03-06

申请人： Novartis AG

发明人： Marta Cosenza ,  Christoph Heusser ,  Julia Neugebauer ,  Eveline Schaadt ,  Stefanie Urlinger ,  Maximilian Woisetschlaeger

IPC分类号： A61K39/395 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/18 ,  A61K47/26 ,  A61K47/10 ,  A61K39/00

摘要： Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

公开(公告)号：US20180179290A1

公开(公告)日：2018-06-28

申请号：US15895055

申请日：2018-02-13

申请人： Novartis AG

发明人： Marta Cosenza ,  Christoph Heusser ,  Julia Neugebauer ,  Eveline Schaadt ,  Stefanie Urlinger ,  Maximilian Woisetschlaeger

IPC分类号： C07K16/28 ,  A61K47/18 ,  A61K9/08 ,  A61K9/19 ,  A61K39/395 ,  A61K47/10 ,  A61K9/00 ,  A61K47/26 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K39/39533 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73

摘要： Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant and/or a free amino acid.